FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a vaccine, including a peptide, bound to a pharmaceutically acceptable carrier, which is not angiotensin II and has an amino acid sequence of formula (X1)m(X2)n(X3)oX4X5HPX6, where X1 represents G or D, X2 represents A, P, M, G or R; X3 represents G, A, H or V; X4 represents S, A, D or Y; X5 represents A, D, H, S, N or I; X6 represents A, L or F, where m, n and o independently on each other equals 0 or 1 on condition that when o equals 0, both m and n equal 0, and when n equals 0, m equals 0, and where the peptide is not a peptide DRVYIHPF. The application of such a peptide for the vaccine production is also characterised.
EFFECT: claimed inventions can be used for the treatment and/or prevention of physical disorders, associated with a rennin-activated angiotensin system.
8 cl, 13 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
PEPTIDES AND THEIR USE IN TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT p53 | 2017 |
|
RU2762089C2 |
ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
ANTI-PVRIG ANTIBODIES AND METHODS OF APPLICATION | 2016 |
|
RU2827926C2 |
POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
NOVEL ENDOLYSINS OF GARDNERELLA AND USE THEREOF | 2020 |
|
RU2820886C2 |
ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
Authors
Dates
2014-12-10—Published
2010-07-23—Filed